Pathalys Pharma presented promising data on Upacicalcet at ASN Kidney Week 2026, demonstrating its efficacy in treating SHPT in hemodialysis patients.

Hansa Biopharma has revealed positive results from the Idefirix PAES study presented at ASN Kidney Week 2026, demonstrating excellent outcomes for kidney transplant patients.

Kibow Therapeutics is set to present significant findings on KT-301 in Stage 4 chronic kidney disease this October at ASN Kidney Week 2026.

Fresenius Medical Care revealed groundbreaking research and advancements in kidney care at ASN Kidney Week 2026, showcasing innovative treatment solutions.

At ASN Kidney Week 2026, DaVita presents vital studies focused on kidney care innovation, addressing critical treatment advancements and patient experiences.

Pathalys Pharma will present critical data on upacicalcet from its Phase 3 program at the ASN Kidney Week 2026, focusing on advancing CKD treatments.

Sobi will present compelling new data on the efficacy of pegcetacoplan for C3G and primary IC-MPGN during ASN Kidney Week 2025 in Houston, Texas.

DaVita marks a quarter-century with groundbreaking studies at ASN Kidney Week 2025, aiming to innovate kidney treatment and improve patient outcomes.